29 results about "Murine tumor" patented technology

The invention relates to application of (E)-2-(4-(dimethylamino) styryl)-6-methoxy-3-methylbenzo [d] thiazole-3-onium in preparation of anti-cancer drugs, and belongs to the technical field of medical application, the structure of (E)-2-(4-(dimethylamino) styryl)-6-methoxy-3-methylbenzo [d] thiazole-3-onium is as shown in the following formula I, the (E)-2-(4-(dimethylamino) styryl)-6-methoxy-3-methylbenzo [d] thiazole-3-onium can inhibit the growth of gastric cancer cells, inhibit the proliferation, invasion and migration of the gastric cancer cells by promoting the autophagy and mitochondrial rupture of AGS and HGC-27 cells of the gastric cancer cells, and block the gastric cancer cells in the G1 stage. Furthermore, in-vivo experiments of mice prove that ZWK-3 can inhibit tumor growth of the mice, shows obvious dose dependence, and does not influence the body weight and visceral indexes of the mice at the same time. Formula I.

The invention relates to the technical field of biological medicines, in particular to a biphenyl aromatic amide compound and application thereof in preparation of a medicine for treating leukemia. The biphenyl aryl amide compound has the activity of efficiently inhibiting leukemia cell proliferation, and provides a safe and efficient candidate drug molecule for treating leukemia; the preparation process of the biphenyl aromatic amide compound is simple and easy to implement, and the reaction conditions are mild; the biphenyl aryl amide compound has excellent performance of inhibiting mouse tumor growth, can be used for anti-leukemia drugs, and has a good development prospect.

The invention belongs to the technical field of medicines, and generally relates to application of N-acetyl-L-tyrosine and an N-acetyltransferase strain for expressing tyrosine in preparation of tumor treatment drugs or anti-tumor immune activation drugs for elderly individuals. Researches find that N-acetyl-L-tyrosine and a tyrosine-expressing N-acetyltransferase strain can significantly inhibit mouse tumors, which shows that the mouse tumors grow slowly or the number of the mouse tumors is reduced. The N-acetyl-L-tyrosine can also regulate anti-tumor immunity, and is expressed as promoting TCF1 expression and increasing the proportion of depleted precursor T cells. In the elderly, the curative effect is particularly prominent. The results show that N-acetyl-L-tyrosine and related strains thereof can be used for tumor treatment and anti-tumor immune aging regulation.

The application discloses a kind of mouse tumor cell culture devices, including device ontology, multiple placing racks are installed in device ontology, multiple placing racks top are all set with placing groove, the inside of multiple placing racks is all provided with access mechanism, access mechanism includes multiple placing plate, the inside of multiple placing plate is all separated into multiple placing chamber by multiple partition, the inside of multiple placing chamber is provided with correction mechanism, and drive mechanism is provided in device ontology.In the application, when multiple culture dishes need to be placed in the device ontology for cultivation, the access mechanism provided in the device ontology can be used to place the multiple culture dishes one by one, without manually placing and adjusting the spacing of the multiple culture dishes repeatedly, improving the efficiency of placing the multiple culture dishes in the device ontology, reducing the time of the culture dishes in the external environment, and improving the survival rate of mouse tumor cell cultivation.

This invention discloses 1-(1H-imidazol-2-yl)-β-carbamoline-3-formyl-Arg-Gly-Asp-Val, its preparation method, its activity in inhibiting tumor cell invasion and migration, and its activity in inhibiting tumor metastasis to the lungs in Lewis mice. Therefore, this invention discloses its application in the preparation of drugs for treating cancer metastasis.

The application discloses application of a separating enzyme inhibitor in preparation of an antitumor drug, and the separating enzyme inhibitor is toxoflavin and a derivative thereof. The compound can inhibit, at a molecular level, cleavage activity of an important proteinase, namely separating enzyme, on one subunit Scc1 of a mucin; at a cellular level, the toxoflavin derivative Walrycin B can inhibit proliferation of cancer cells such as human cervical cancer (HeLa), liver cancer (HepG2), breast cancer (MCF-7) and prostate cancer (PC3), and can arrest the cell cycle of the cancer cells at a G2 / M phase; and at an allogeneic transplantation tumor animal model, the Walrycin B can significantly inhibit growth of a mouse tumor.

The application belongs to the technical field of animal model construction, and discloses a method for establishing a tumor-bearing animal model for an OCT system, wherein a SD rat supratentorial brain parenchymal glioma model, a SD rat chiasma glioma model and a SD rat brain stem glioma model are constructed by using a C6 cell line; a rat sciatic nerve sheath tumor model and a rat trigeminal nerve RT4 tumor model are constructed by using an RT4 cell line to obtain a SD rat RT4 tumor cell animal model; and a BALB / c nude mouse U87MG tumor cell animal model and a BALB / c nude mouse IOMM-Lee tumor cell animal model are constructed by using a U87MG cell line and an IOMM-Lee cell line, respectively. The application successfully constructs a rat brain glioma model, a chiasma glioma model, a trigeminal nerve sheath tumor model, a sciatic nerve sheath tumor model, a nude mouse brain glioma model and a nude mouse sciatic nerve meningioma model.

The invention discloses application of lactobacillus mucosa or equol in preparation of a sensitizing colorectal cancer immunotherapy drug. Lactobacillus mucosa LMSJ001 is preserved in the China General Microbiological Culture Collection Center (CGMCC), and the preservation number is CGMCC NO.29885. The lactobacillus mucosa LMSJ001 is preserved in the China General Microbiological Culture Collection Center (CGMCC). According to the application disclosed by the invention, the curative effect of the PD-1 antibody on microsatellite stable (immunotherapy insensitive) colorectal cancer mice is enhanced through the lactobacillus mucosa LMSJ001, and the tumor growth of the colorectal cancer mice can be remarkably inhibited through prophylactic or therapeutic gavage. The lactobacillus mucosa LMSJ001 can generate a metabolite equol, the equol can sensitize the curative effect of a PD-1 antibody on microsatellite stable (immunotherapy insensitive) colorectal cancer mice, the colorectal cancer is remarkably inhibited in vivo and in vitro, and ferroptosis of colorectal cancer cells is promoted. Based on the unique functions, the lactobacillus mucosa LMSJ001 or a metabolite equol of the lactobacillus mucosa LMSJ001 can be cooperated or complemented with other means, can be used for preparing a pharmaceutical composition, and has a very wide application prospect.

The invention discloses a fusion protein of neutrophil elastase as well as a preparation method and application of the fusion protein. The fusion protein comprises an optimized human neutrophil elastase (ELANE) fragment and an optimized human alpha2-macroglobulin (A2M) fragment; the amino acid sequence of the fusion protein is as shown in SEQ ID NO.8. The use of ELANE is limited due to intolerance to serine protease inhibitors (such as alpha-1-antitrypsin, A1AT). The optimized ELANE fragment and the optimized A2M fragment are connected to form the fusion protein, the fusion protein has high enzymatic activity, the tolerance to A1AT is greatly improved, and 83.3% of enzyme activity can still be maintained after the fusion protein acts for 2 hours through high-concentration A1AT (19200 nM). The fusion protein can efficiently eliminate mouse tumors and is safe to mice. The fusion protein is simple in preparation process and easy to industrially amplify, and a new strategy is provided for tumor treatment.

The present invention discloses a nanosystem for tumor radioimmunotherapy, its preparation method and application, belonging to the technical field of biomedicine. This system is engineered to modify bacterial outer membrane vesicles (OMVs) to carry magnetite nanoparticles (Fe3O4NPs) and the ATR inhibitor VE822. By using the synergistic effect of the Fenton reaction activity of Fe3O4NPs and the inhibition of DNA damage repair by the ATR inhibitor, DNA damage is amplified and the DNA damage response (DDR) is inhibited, the generation of hydroxyl radicals (·OH) under radiation is enhanced, the radiation resistance of tumor cells is reduced, the immune response is reactivated, the infiltration of effector T cells into tumors is improved, and the growth of tumors in mice is significantly inhibited, providing an effective strategy for tumor radioimmunotherapy.

The invention discloses a PD-1 / PD-L1 immunotherapy acquired drug-resistant mouse subcutaneous tumor model construction method based on in-vivo multi-dimensional immune landscape evolution, and relates to the field of animal model construction. Comprising the following steps: preparing tumor cells: resuscitating and amplifying an MC38 colonic adenocarcinoma cell strain, and preparing a single-cell suspension; establishing a basic model: inoculating the MC38 single-cell suspension under the skin of a homologous C57BL / 6 mouse, and establishing a tumor-bearing mouse model; drug resistance induction and screening: after the tumor grows to a predetermined volume, applying continuous treatment pressure of an anti-PD-1 or anti-PD-L1 antibody to the tumor-bearing mouse. Firstly, the tumor volume of mice in a treatment group is compared with the average volume of a control group at the same time point, response mice with the tumor volume obviously smaller than that of the control group are screened out, and primary drug-resistant individuals are excluded. Performing dynamic immune monitoring sampling; and processing and analyzing the sample. The preclinical model has the characteristics of repeatability and dynamic monitoring, and overcomes the defects of the existing preclinical model.

The invention belongs to the field of medicines, and discloses an antibody conjugate, the antibody conjugate is obtained by coupling a connecting structure, bortezomib and an antibody, the antibody conjugate has extremely strong drug sensitivity, and when the antibody conjugate is singly used or combined with cis-platinum, the antibody conjugate shows a remarkable inhibition effect on activity of proteasomes in MDA-MB-231 cells and mouse tumors. Meanwhile, the invention also discloses application and a medicine based on the antibody conjugate.

The invention discloses an application of miR408 in preparation of a medicine for treating tumors. The invention finds that the ginseng miR408 transferred into the body of a mouse through the exosome can still maintain better integrity and stability; through overexpression of ginseng miR408 in breast cancer MCF-7 and MDA-MB-231 cells, it is found that after overexpression of ginseng miR408, proliferation, migration and invasion of tumor cells can be significantly inhibited, cell apoptosis can be promoted, and CCND1 mRNA and protein expression levels can be reduced; a mouse gavage experiment also shows that the ginseng miR408 can significantly inhibit the growth of breast cancer mouse tumors. The application shows that the ginseng miR408 can enter the body to treat the breast cancer in an exosome manner, a new way is provided for treating the breast cancer, the problems of untoward effects and the like existing in existing medicine treatment are solved, and a new action mechanism and a new research direction are provided for ginseng in the aspect of breast cancer treatment.

The invention discloses a mouse tumor cell culture device which comprises a device body, a plurality of placing frames are installed in the device body, placing grooves are formed in the tops of the placing frames, storing and taking mechanisms are arranged in the placing frames, and each storing and taking mechanism comprises a plurality of placing plates. The interiors of the multiple containing plates are divided into multiple containing cavities through multiple partition plates, correction mechanisms are arranged in the multiple containing cavities, and a driving mechanism is arranged in the device body. According to the device, when multiple culture dishes need to be placed in the device body for culture, the multiple culture dishes can be sequentially placed through the access mechanism arranged in the device body, the multiple culture dishes do not need to be manually and repeatedly placed and the distance between the multiple culture dishes does not need to be adjusted, and the efficiency of placing the multiple culture dishes in the device body is improved; the time of the culture dish in the external environment is shortened, so that the survival rate of mouse tumor cell culture is improved.

This invention belongs to the field of medicinal chemistry, specifically relating to ionizable phospholipids for nucleic acid delivery and their applications. The technical problem this invention aims to solve is the limited variety of ionizable phospholipids currently available for preparing LNPs for mRNA delivery. The technical solution of this invention is to provide a novel ionizable phospholipid molecule that can be used to prepare nucleic acid delivery carriers and LNP formulations prepared based on it. LNP formulations prepared using the ionizable phospholipids of this invention as raw materials exhibit good stability. Experiments show that the LNPs of this invention can efficiently deliver therapeutic RNA to various human and murine tumor cells and achieve high levels of protein expression, demonstrating unique advantages and promising application prospects in this field.

The present invention relates to the field of biomedicine, and more particularly to biphenyl arylamide compounds and their use in the preparation of leukemia treatment drugs. The biphenyl arylamide compounds have the activity of effectively inhibiting the proliferation of leukemia cells, providing safe and effective candidate drug molecules for the treatment of leukemia. The preparation process of the biphenyl arylamide compounds is simple and easy, and the reaction conditions are mild. The biphenyl arylamide compounds have excellent performance in inhibiting tumor growth in mice, and can be used as anti-leukemia drugs, showing good development prospects.

The invention relates to application of galectin-1 (Gal-1) as an immune checkpoint in preparation of a tumor immunotherapy drug and the drug, and provides a new strategy for tumor immunotherapy targeting the new immune checkpoint. The lactose and the derivative thereof can inhibit the immune checkpoint by competing Gal-1 on the surfaces of cancer cells and immune cells, and have no obvious toxic or side effect; by knocking out B4GATL1 to reduce protein galactosylation, the Gal-1 level of tumor metastasis to T cells can be remarkably reduced, so that the activation and function of the T cells are enhanced; besides, the lactose synthetase component LALBA is overexpressed in the mouse tumor, so that de novo synthesis of lactose in the tumor microenvironment can be realized, and further the CD8 + T cell mediated immune response is enhanced. In combination with the anti-tumor effect and economic cost of lactose, a wide and feasible thought is provided for cancer treatment.

The present application relates to the technical field of traditional Chinese medicine, and particularly relates to application of a traditional Chinese medicine composition in preparation of a medicine for preventing and treating uterine fibroids. The traditional Chinese medicine composition comprises Gleditsia sinensis L. thorns, giant knotweed, dandelion, Sargentgloryvine stem, radix codonopsis, smilax, red peony root, salvia miltiorrhiza, lindera and corydalis. The traditional Chinese medicine composition can obviously inhibit tumor size of uterine fibroid rats, reduce uterine coefficient, reduce the number and size of myoma, and improve the pathological state of the uterus; and can reduce the content of E2, P and ER in serum, and has a good effect on treating uterine fibroids.

The disclosure provides methods and compositions, e.g., kits and microarray, for assessing the immune response in a murine tumor model based on the expression of a gene panel that characterizes tumor immune interactions.

The invention discloses an application of a bacterial protein in preparation of a medicine for inhibiting colorectal cancer. The bacterial protein is a CWBR-CP protein derived from Hungata hedwayi. The invention further discloses an application of the bacterial protein in preparation of a medicine for inhibiting colorectal cancer. A recombinant expression vector containing a coding gene of the CWBR-CP protein is introduced into Escherichia coli to construct recombinant Escherichia coli and express the recombinant Escherichia coli, thalli of the expressed recombinant Escherichia coli are separated and extracted, and the bacterial protein with anticancer activity is obtained. The prepared CWBR-CP protein can significantly reduce the size and weight of the tumor of a mouse with colorectal cancer induced by azomethane / dextran sodium sulfate and increase the proportion of CD80 < + > macrophages to CD80 < + > CD86 < + > macrophages, it is prompted that CWBR-CP can promote polarization of M1 macrophages to inhibit the progress of CRC, a new means capable of effectively inhibiting the occurrence and development of colorectal cancer is expected to be obtained, and the CWBR-CP protein has a broad application prospect. And the method has huge development prospects and application values.

The invention discloses an HPV18 recombinant lentiviral vector, a cell and a construction method and application of a mouse tumor model. The recombinant lentiviral vector has an HPV18E6 expression cassette and an E7 expression cassette; the structures of the HPV18E6 and E7 expression cassettes are a first promoter, an E6 first 2A peptide, a first selection marker, a second promoter, an E7 second 2A peptide and a second selection marker; the first promoter and the second promoter are different and are selected from a CMV promoter, an EF1a promoter, an SV40 promoter, a beta-actin promoter, a CAG promoter and a PGK promoter; the first 2A peptide and the second 2A peptide are each independently selected from a P2A peptide and a T2A peptide; one of the first selection marker and the second selection marker is a fluorescent gene, and the other one is an antibiotic gene. According to the invention, high expression of HPV18E6 and E7 proteins is realized through HPV18E6 and E7 expression cassettes.

The invention provides ginseng oligopeptide with an anti-tumor effect and a preparation method of the ginseng oligopeptide. The ginseng oligopeptide is prepared by performing double-enzyme enzymolysis on ginseng protein, the oligopeptide is further screened and identified to obtain the Rs-A-2 active anti-cancer peptide, and the anti-cancer peptide has a relatively good effect of inhibiting cancer cell proliferation. Meanwhile, animal experiments prove that the oligopeptide and / or the anti-cancer peptide can effectively reduce expression of target surface genes and inhibit growth of mouse tumors, and the anti-cancer peptide is beneficial to improving the immune function of tumor-bearing mice. After the oligopeptide is prepared into a medicine, the medicine has a better anti-tumor effect and a wide application prospect.

The invention belongs to the field of medicines, and discloses an antibody conjugate which comprises aminated bortezomib, a connecting structure and an antibody, one end of the connecting structure is carboxyl, and the other end of the connecting structure is a maleimide group connected with an antibody; the aminated bortezomib comprises bortezomib and amino which is connected to phenyl of the bortezomib through a covalent bond; the aminated bortezomib is connected with the connecting structure through an amidation reaction between the amino group and the carboxyl group of the connecting structure. The antibody conjugate has extremely high drug sensitivity, and shows a remarkable inhibition effect on activity of proteasomes in MDA-MB-231 cells and mouse tumors after the antibody conjugate is singly used or combined with cis-platinum. Meanwhile, the invention also discloses application and a medicine based on the antibody conjugate.

This invention discloses the application of miR408 in the preparation of drugs for treating tumors. The invention found that ginseng miR408 delivered to mice via exosomes maintained good integrity and stability. Overexpression of ginseng miR408 in breast cancer MCF-7 and MDA-MB-231 cells significantly inhibited tumor cell proliferation, migration, and invasion, promoted apoptosis, and downregulated CCND1 mRNA and protein expression levels. Gavage experiments in mice also showed that ginseng miR408 significantly inhibited tumor growth in breast cancer mice. This indicates that ginseng miR408 can enter the body via exosomes to treat breast cancer, providing a new approach to breast cancer treatment, overcoming the adverse reactions of existing drug therapies, and offering a new mechanism of action and research direction for ginseng in breast cancer treatment.

The invention discloses application of a 3-aryl-4-indolyl maleimide derivative in preparation of a medicine for treating pancreatic cancer, and relates to the technical field of medicine application. The structural formula of the 3-aryl-4-indolyl maleimide derivative is shown in the specification, and the structural formula of the 3-aryl-4-indolyl maleimide derivative is shown in the specification. R1 is selected from one of hydrogen, C1-C5 alkyl and C1-C5 alkoxy, and R2 is selected from one of hydrogen, C1-C5 alkyl, halogen and C1-C5 halogenated alkyl. The method comprises the following steps: firstly synthesizing a key compound, evaluating and measuring IC50 of the key compound to isoQC, then simulating a pancreatic cancer tumor model through subcutaneous modeling, regularly dosing the pancreatic cancer model through intraperitoneal injection, monitoring the tumor growth condition of a pancreatic cancer mouse, monitoring the body weight, ending the dosing at a proper time, and killing the mouse. And main organs and tumor tissues are taken out for related detection. Results show that the series of compounds have good isoQC inhibitory activity and pancreatic cancer treatment effect.

The invention belongs to the technical field of medicines, discloses application of a compound CA3 in inhibiting leukemia cell proliferation and treating leukemia, and particularly discloses application of the compound CA3 shown as a formula (I) in treating leukemia. Pharmacological experiments prove that the CA3 can obviously inhibit the proliferation of leukemia cells HL-60 (the IC50 value is 5.4 * 10 <-7 > M); the tumor volume of an HL-60 cell ectopic transplantation NOD-SCID mouse is reduced 11 days after the CA3 is administered, and the tumor weight of the HL-60 cell ectopic transplantation NOD-SCID mouse is reduced 14 days after the CA3 is administered. Experimental results show that the CA3 significantly inhibits leukemia cell proliferation at a cellular level and significantly reduces leukemia tumor growth at an animal level.

The invention belongs to the technical field of biological medicines, and particularly relates to a parabacteroides coumarini-sourced membrane vesicle as well as a preparation method and application thereof. The membrane vesicle is prepared through a gradient centrifugation method, the average particle size of the membrane vesicle is 115 nm, the Zeta potential is-12 mV, and the concentration is 2.69 * 10 < 11 > + / -1.22 * 10 < 9 > particles / mL; in-vitro experiments prove that the parabacteroides coumarini-sourced membrane vesicles can significantly inhibit the proliferation activity of breast cancer cells; in-vivo experiments show that the parabacteroides coumarini-sourced membrane vesicles can significantly inhibit tumor growth of breast cancer mice, and have good biological safety; mechanism discussion shows that the parabacteroides coumarini-sourced membrane vesicles mainly play an anti-tumor role by promoting the infiltration level of CD8 + T cells in a tumor microenvironment; in conclusion, the parabacteroides coumarini-sourced membrane vesicles have good development potential and application prospects in breast cancer immunotherapy.

This invention relates to the application of (E)-2-(4-(dimethylamino)styryl)-6-methoxy-3-methylbenzo[d]thiazol-3-onthium in the preparation of anticancer drugs, belonging to the field of pharmaceutical technology. The structure of (E)-2-(4-(dimethylamino)styryl)-6-methoxy-3-methylbenzo[d]thiazol-3-onthium is shown in Formula I below. The (E)-2-(4-(dimethylamino)styryl)-6-methoxy-3-methylbenzo[d]thiazol-3-onthium of this invention can inhibit the growth of gastric cancer cells. By promoting autophagy and mitochondrial fragmentation in gastric cancer cells AGS and HGC-27, it inhibits the proliferation, invasion, and migration of gastric cancer cells and arrests them in the G1 phase. Furthermore, in vivo experiments in mice have confirmed that ZWK-3 can inhibit tumor growth in mice in a significant dose-dependent manner, without affecting mouse body weight or visceral indices. Formula I.

The invention provides a preparation method of black phosphorus-based monatomic nano-enzyme, which comprises the following steps: dispersing a black phosphorus carrier in a solution containing a metal or non-metal precursor in an ultralow temperature environment to form a uniform suspension; irradiating by adopting an ultraviolet light source, and inducing metal or non-metal ions to be directionally anchored at defect sites on the surface of the black phosphorus carrier; a metal / nonmetal-black phosphorus coordination structure is formed through ultralow-temperature light-induced reduction, and the monatomic nano-enzyme is obtained. The invention provides an in-vivo anti-tumor effect of the black phosphorus-based monatomic nano-enzyme material. And the treated mouse tumor can be completely ablated. In the treatment process, the weight of the mouse is not changed, and organs are not damaged, so that the biological safety of the treatment is indicated. Mouse tumor tissues show more serious cell nucleus atrophy and cell apoptosis, which shows that the treatment has excellent clinical application prospects.